Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Experimental: TIL+ Nivolumab

Nivolumab infusion every 3 weeks prior to lymphodepletion chemotherapy with cyclophosphamide/fludarabine, TIL infusion and interleukin-2. Then nivolumab infusion every 4 weeks up to 12 months.

Biological: Tumor-infiltrating Lymphocytes (TIL)

Tumor harvest for TIL growth in the lab: A sample of the participant’s tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.

Other Name: TIL

Drug: Nivolumab

Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.

Other Name: Opdivo

Drug: Cyclophosphamide

Cyclophosphamide will be administered on days -7 and -6.

Other Name: Cytoxan

Drug: Fludarabine

Fludarabine will then be infused per institutional standard on Days -7 to -3.

Other Name: Fludara

Other: Tumor-infiltrating Lymphocyte Therapy

On day 0, all patients will receive a dose infusion TIL cells.

Other Name: TIL

Drug: Interleukin-2 (IL2)

Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.

Other Name: IL2

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 13, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments